Skip to main content
Better together.
Fred Hutch
Seattle Children's
UW Medicine
Enter the terms you wish to search for.

Related Nav

  • Contact Us
  • Donate and Volunteer
  • For Healthcare Professionals

Main navigation

  • New Patients
    • Why Seek Treatment at SCCA?
    • Preparing for Your First Visit
    • Locations
    • Transportation
    • Insurance Coverage and Bills
    • Services and Support
    • Patient Stories
  • Diseases and Treatments
    • Treatment Options
    • Clinical Trials
    • During Your Treatment
    • Coping with Side Effects
    • Palliative Care
    • Self Care
  • After Treatment
    • Coping with After Effects
    • Survivorship Events
  • Resources
    • Resources for Caregivers
    • For Children and Teens
    • Emotional and Spiritual Support
    • Health and Nutrition
    • Services and Support
    • Medical Record Request
Resources for Patients and Caregiviers
Your support team includes nutritionists, emotional support, caregiver resources, and so much more.
Learn more
Real Stories from Real Patients
Our patients share their stories of hope, care and outcomes
Learn more
Help Us Help Future Patients
Our patient advisory board helps us continually improve the patient experience. Join us.
Learn more
Caresi
Patient care app
Caresi® is a personal health app, created by SCCA for you, our patient. With the app, view your schedule, access lab results, contact care teams and review resources.
Learn more
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

A Study Evaluating Escalating Doses of 211At-labeled anti-CD45 MAb BC8-B10 (211At-BC8-B10) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Investigator

Brenda M. Sandmaier, MD

Brenda
M.
Sandmaier
MD
Trial Phase
Phase I/II
Study Number
NCT03128034
Local Study ID
9595
Trial Contact Phone
800-804-8824 / 206-606-1024
Summary
This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before donor stem cell transplant.
Trial Eligibility

Ages Eligible for Study: 18 Years and older (Adult, Senior)
Sexes Eligible for Study: All

- Patients must have advanced AML, ALL or high-risk MDS meeting one of the following descriptions:
-- * AML or ALL beyond first remission (i.e., having relapsed at least one time after achieving remission in response to a treatment regimen)
-- * AML or ALL representing primary refractory disease (i.e., having failed to achieve remission at any time following one or more prior treatment regimens)
-- * AML evolved from myelodysplastic or myeloproliferative syndromes
-- * MDS expressed as refractory anemia with excess blasts (RAEB)
-- * Chronic myelomonocytic leukemia (CMML) by French-American-British (FAB) criteria

- Patients not in remission must have CD45-expressing leukemic blasts; patients in remission do not require phenotyping and may have leukemia previously documented to be CD45 negative
- Patients should have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea or similar agent is allowed)
- Patients must have an estimated creatinine clearance greater than 50/ml per minute by the following formula (Cockcroft-Gault); serum creatinine value must be within 28 days prior to registration
- Patients must have normal hepatic function (bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]
- Eastern Cooperative Oncology Group (ECOG) = 70
- Patients must be free of uncontrolled infection

- Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows:
-- * Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1; phenotypic identity must be confirmed by high-resolution typing
-- * Unrelated donor:
--- ** Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR
--- ** Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing
--- ** Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment; the recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before hematopoietic cell transplant (HCT); if the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained; the donor should be excluded if any of the cytotoxic cross match assays are positive; for those patients with an HLA Class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is an absolute donor exclusion
-- * Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed
Other eligibility criteria may apply.

Trial Exclusions

- Patients may not have symptomatic coronary artery disease and may not be on cardiac medications for anti-arrhythmic or inotropic effects
- Left ventricular ejection fraction
- Corrected diffusing capacity of the lungs for carbon monoxide (DLCO)
- Liver abnormalities: fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or symptomatic biliary disease
- Patients who are known to be seropositive for human immunodeficiency virus (HIV)
- Perceived inability to tolerate diagnostic or therapeutic procedures
- Active central nervous system (CNS) leukemia at time of treatment
- Women of childbearing potential who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+] or breast feeding
- Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
- Inability to understand or give an informed consent
- Allergy to murine-based monoclonal antibodies
- Known contraindications to radiotherapy
Other exclusion criteria may apply.

Trial Keywords
Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Lymphoproliferative Disorders; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Leukemia, Lymphoid; Immunoproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Chronic Myelomonocytic (CMML); Preleukemia; Bone Marrow Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases
See this trial at ClinicalTrials.gov

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.

Patient Guide to Clinical Trials
Locations
Request an Appointment
Find a Physician

Connect With Us

  • Contact Us
  • Request an Appointment
  • Careers
  • Referring Doctors
  • Phone Directory
  • Press and News
  • Social Media
  • Community Benefit
Follow Us
http://twitter.com/SeattleCCA
http://www.facebook.com/SeattleCancerCareAlliance
http://www.youtube.com/user/SeattleCancerCare
http://www.sccablog.org/
https://www.nccn.org/Members/Profiles/Default.aspx?MemberId=8
https://www.qualitycheck.org/quality-report/?bsnid=328340

SCCA Locations

  • South Lake Union
  • SCCA Issaquah
  • SCCA Peninsula
  • UW Medical Center
  • EvergreenHealth
  • UW Medicine’s Northwest Hospital
  • SCCA Proton Therapy Center
  • Seattle Children's

Seattle Cancer Care Alliance
825 Eastlake Ave. E
PO Box 19023
Seattle, WA 98109­-1023

 

 

 

 

Patient Educational Email Invitation Exposes Patient Information

©2004-2019 Seattle Cancer Care Alliance. All Rights Reserved.

footer legal links

  • SCCA Links
  • Privacy Policy
  • Public Care Policy
  • Disclaimer
  • Financial Assistance
  • Notice of Nondiscrimination

Seattle Cancer Care Alliance is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read EEO is the Law poster here. 

Better together.
Fred Hutch
Seattle Children's
UW Medicine